Good morning, everyone, and how are you today? We are doing swell, thank you, helped along by a bright, shiny sun enveloping the chilly Pharmalot campus, where the short person has left for the local schoolhouse and the official mascots are lounging about. We, however, are as busy as ever, quaffing cups of stimulation and foraging for tidbits. Speaking of which, here a few. Hope your day goes well and you conquer the world …

Multiple pharmaceutical executives are expected to add their names to a letter expressing concern about the effects of immigration restrictions on the industry, BioCentury reports. More than 160 biotech industry executives have already signed the letter, which was published earlier this week by Nature Biotechnology and included broader criticism of the implications of the new restrictions for the US.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy